Australia · Delayed Price · Currency is AUD Racura Oncology Company Description
Racura Oncology Ltd operates as a clinical biopharmaceutical company focuses on the cancer care.
Its lead asset is RCDS1 (E,E-bisantrene), a small molecule anticancer agent that functions through G4-DNA and RNA binding to potent inhibition of the cancer growth regulator MYC.
The company is advancing a proprietary formulation of RCDS1 (RC220) to address the unmet needs of patients across various oncology indications with Phase 3 clinical programs in acute myeloid leukaemia, Phase 1a/b program in mutant epidermal growth factor receptor non-small cell lung cancer (EGFRm NSCLC), and a Phase 1a/b program in combination with the anthracycline doxorubicin.
It has collaborations with Astex, MD Anderson, Sheba City of Health, UNC School of Medicine, University of Wollongong, and University of Newcastle.
The company was formerly known as Race Oncology Ltd and changed its name to Racura Oncology Ltd in December 2025.
Racura Oncology Ltd was incorporated in 2011 and is headquartered in Sydney, Australia.
| Country | Australia |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Daniel Tillett |
Contact Details
Address: Gateway, 1 Macquarie Place Sydney, NSW 2000 Australia | |
| Phone | 61 2 8051 3043 |
| Website | racuraoncology.com |
Stock Details
| Ticker Symbol | RAC |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU000000RAC3 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Daniel Tillett | Chief Executive Officer, MD and Director |
| Dr. Peter Michael Smith Ph.D. | Executive Chairman |
| Brendan Brown | Chief Financial Officer |
| Dr. Sophia Moscovis | Vice President of Operations and Strategy |
| Dr. Jose L. Iglesias M.D. | Chief Medical Officer |
| Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D. | Company Secretary |